Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$2.94 USD
+0.20 (7.30%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $2.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Werewolf Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 20 | 16 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 20 | 16 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 60 | 72 | 50 | 22 | 10 |
Income After Depreciation & Amortization | -41 | -56 | -50 | -22 | -10 |
Non-Operating Income | 6 | 2 | 0 | 7 | 0 |
Interest Expense | 3 | 0 | 0 | 0 | 0 |
Pretax Income | -37 | -54 | -50 | -15 | -10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -37 | -54 | -50 | -15 | -10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -37 | -54 | -50 | -15 | -10 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -39 | -55 | -50 | -22 | -10 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -41 | -56 | -50 | -22 | -10 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 35.65 | 28.86 | 18.46 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.05 | -1.86 | -10.94 | NA | NA |
Diluted Net EPS (GAAP) | -1.05 | -1.86 | -10.94 | -28.09 | NA |
Fiscal Year end for Werewolf Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.74 | 1.50 | 5.90 | 8.08 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.74 | 1.50 | 5.90 | 8.08 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 17.91 | 14.46 | 15.15 | 14.15 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -17.17 | -12.96 | -9.25 | -6.07 |
Non-Operating Income | NA | 1.97 | 4.10 | 0.97 | 0.97 |
Interest Expense | NA | 1.00 | 3.14 | 0.00 | 0.00 |
Pretax Income | NA | -16.19 | -12.00 | -8.29 | -5.10 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -16.19 | -12.00 | -8.29 | -5.10 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -16.19 | -12.00 | -8.29 | -5.10 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 41.61 | 36.57 | 35.65 | 35.56 |
Diluted EPS Before Non-Recurring Items | NA | -0.39 | -0.33 | -0.23 | -0.14 |
Diluted Net EPS (GAAP) | NA | -0.39 | -0.34 | -0.23 | -0.14 |